Head-to-head trial shows Eli Lilly’s oral GLP-1 orforglipron outperforms oral semaglutide

A clinical trial for diabetes that pit orforglipron, a diabetes and weight-loss pill developed by Eli Lilly, against oral ...
The American Journal of Managed Care

Orforglipron Outperforms Oral Semaglutide in Head-to-Head Type 2 Diabetes Trial

An investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist, orforglipron (Eli Lilly), demonstrated superior ...

Phoenix NP Announces Expanded Access to FDA-Approved Wegovy (Semaglutide), Including Injection and Newly Available Oral Form, Through Its Arizona Telehealth Program

PHOENIX, AZ - February 27, 2026 - PRESSADVANTAGE - Phoenix NP, a women-focused telehealth medical practice based in ...
MedPage Today on MSN

Novel GLP-1 Pill Tops Oral Semaglutide for Diabetes

Orforglipron carried more side effects, however ...

New GLP-1 pill orforglipron outperforms oral semaglutide in yearlong diabetes trial

A novel GLP-1 receptor agonist (RA) pill called orforglipron leads to a larger reduction in blood sugar levels after a year ...

New oral pill beats previous alternatives and shows 8% weight loss in clinical trials

Eli Lilly’s new oral pill, orforglipron, led to up to 8% weight loss in clinical trials, outperforming existing oral ...
Healio

Orforglipron confers greater HbA1c decline than oral semaglutide in type 2 diabetes

Once-daily orforglipron induced greater reductions in HbA1c and body weight than once-daily oral semaglutide for adults with type 2 diabetes, according to data from the ACHIEVE-3 trial published in ...
Everyday Health on MSN

New GLP-1 Pill for Diabetes Shows Strong Results in Late-Stage Trial

Drugmaker Lilly said its experimental pill, orforglipron, produced better blood sugar and weight loss for diabetes patients results in a new head-to-head clinical trial.

Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in Th…

Eli Lilly and Company (NYSE: LLY) today announced detailed results from ACHIEVE-3, the first head-to-head Phase 3 trial ...
The BMJ

New weight loss pill outperforms oral semaglutide for diabetes patients, study reports

Orforglipron, a new glucagon-like peptide-1 (GLP-1) receptor agonist pill, leads to greater glycaemic control and weight loss for patients with type 2 diabetes than oral semaglutide (Rybelsus), ...

BreezeMeds GLP-1 Weight Loss 2026: Compounded Semaglutide and Tirzepatide Pricing (From $199), FDA Regulatory Status Examined

A 2026 Informational Overview of the BreezeMeds Compounded GLP-1 Telehealth Weight Loss Platform, Semaglutide and Tirzepatide Medication Formats, Published Pricing Structure, 503A Compounding Pharmacy ...